Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia:: A multicenter study of 51 patients

被引:64
|
作者
Morschhauser, F
Cayuela, JM
Martini, S
Baruchel, A
Rousselot, P
Socié, G
Berthou, P
Jouet, JP
Straetmans, N
Sigaux, F
Fenaux, P
Preudhomme, C
机构
[1] CHU Lille, Serv Malad Sang, F-59037 Lille, France
[2] CHU Lille, Lab Hematol A, F-59037 Lille, France
[3] INSERM, U524, F-59045 Lille, France
[4] INSERM, U462, Lab Hematol Mol, Paris, France
[5] Hop St Louis, Serv Hematol Pediat Hematol Clin Adulte & Greffe, Paris, France
[6] CHU Brest, Hematol Serv, F-29285 Brest, France
[7] Clin Univ St Luc, B-1200 Brussels, Belgium
关键词
D O I
10.1200/JCO.2000.18.4.788
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Most studies using various reverse transcription polymerase chain reaction (RT-PCR) techniques reported that the detection of the AML1-ETO fusion transcript was a common finding in long-term complete remission (CR) in acute myeloid leukemia (AML) with t(8;21) translocation, However, larger prospective studies with interlaboratory quality control may be important to investigate more precisely the clinical usefulness of studying minimal residual disease with RT-PCR in t(8;21) AML. Patients and Methods: We collected 223 marrow samples from 51 patients with t(8;21) AML diagnosed in five centers and tested all samples by two different RT-PCR techniques (a nested technique and a one-step technique, with a sensitivity of 10(-6) and 10(-5), respectively) in two different laboratories. Results: Samples from 14 patients in long persistent CR (median follow-up duration, 112 months) were taken at least twice, and all were PCR-negative by both techniques, Samples were prospectively taken from 37 patients after achievement of first CR and/or second CR, before intensive consolidation treatment, and every 3 to 6 months after completion of therapy. Patients who converted to PCR negativity with the one-step technique (60%) or both techniques (48%) after CR achievement had a longer CR duration than those with persistently positive PCR results (two-sided log-rank test, P = .0001), Patients who became PCR-negative with the one-step technique before intensive consolidation (23%) had a lower relapse rate (11% v 72%) and a longer CR duration than those who remained persistently PCR-positive at that point (two-sided log-rank test, P = .0015). Conclusion: Patients with AML with t(8;21) in longterm remission were all PCR-negative. In prospectively studied patients, a good correlation was found between negative PCR results and absence of relapse. Early negative results with the one-step RT-PCR technique, before consolidation treatment, seemed to carry an especially good prognosis, suggesting that RT-PCR analysis could help in choosing the type of consolidation therapy in patients with t(8;21) AML, (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:788 / 794
页数:7
相关论文
共 50 条
  • [31] Quantitative analysis of MDR-1 gene expression in acute myeloid leukemia by reverse transcription polymerase chain reaction
    Cao, QX
    Schulz, A
    Scheid, C
    Wickramanayake, PD
    AMERICAN JOURNAL OF HEMATOLOGY, 1996, 52 (04) : 329 - 329
  • [32] Prognostic significance of peritoneal minimal residual disease in gastric cancer detected by reverse transcription-polymerase chain reaction
    Oyama, K
    Terashima, M
    Takagane, A
    Maesawa, C
    BRITISH JOURNAL OF SURGERY, 2004, 91 (04) : 435 - 443
  • [33] Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations
    W-C Chou
    J-L Tang
    S-J Wu
    W Tsay
    M Yao
    S-Y Huang
    K-C Huang
    C-Y Chen
    C-F Huang
    H-F Tien
    Leukemia, 2007, 21 : 998 - 1004
  • [34] Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations
    Chou, W-C
    Tang, J-L
    Wu, S-J
    Tsay, W.
    Yao, M.
    Huang, S-Y
    Huang, K-C
    Chen, C-Y
    Huang, C-F
    Tien, H-F
    LEUKEMIA, 2007, 21 (05) : 998 - 1004
  • [35] Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
    Tobal, K
    Newton, J
    Macheta, M
    Chang, J
    Morgenstern, G
    Evans, PAS
    Morgan, G
    Lucas, GS
    Yin, JAL
    BLOOD, 2000, 95 (03) : 815 - 819
  • [36] Prognostic value of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) using polymerase chain reaction (PCR)
    Katsibardi, K.
    Palathanasiou, C.
    Moschovi, M.
    Karamolegou, K.
    Lambrou, G. I.
    Tzortzatou-Stathopoulou, F.
    PEDIATRIC BLOOD & CANCER, 2007, 49 (03) : 387 - 387
  • [37] DETECTION OF MINIMAL RESIDUAL DISEASE IN T-CELL ACUTE LYMPHOBLASTIC-LEUKEMIA USING POLYMERASE CHAIN-REACTION PREDICTS IMPENDING RELAPSE
    NEALE, GAM
    MENARGUEZ, J
    KITCHINGMAN, GR
    FITZGERALD, TJ
    KOEHLER, M
    MIRRO, J
    GOORHA, RM
    BLOOD, 1991, 78 (03) : 739 - 747
  • [38] DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA BY IMMUNOLOGICAL MARKER ANALYSIS AND POLYMERASE CHAIN-REACTION
    VANDONGEN, JJM
    BREIT, TM
    ADRIAANSEN, HJ
    BEISHUIZEN, A
    HOOIJKAAS, H
    LEUKEMIA, 1992, 6 : 47 - 59
  • [39] THE USE OF THE POLYMERASE CHAIN-REACTION TO DETECT MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    STEWARD, CG
    GOULDEN, NJ
    POTTER, MN
    OAKHILL, A
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (08) : 1192 - 1198
  • [40] Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
    Perea, G
    Lasa, A
    Aventín, A
    Domingo, A
    Villamor, N
    de Llano, MPQ
    Llorente, A
    Juncà, J
    Palacios, C
    Fernández, C
    Gallart, M
    Font, L
    Tormo, M
    Florensa, L
    Bargay, J
    Martí, JM
    Vivancos, P
    Torres, P
    Berlanga, JJ
    Badell, I
    Brunet, S
    Sierra, J
    Nomdedéu, JF
    LEUKEMIA, 2006, 20 (01) : 87 - 94